Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

MY-5445

PDE inhibitor
 
BML-PD155-0010 10 mg 168.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-270-085

Selective inhibitor of cGMP-specific phosphodiesterase (PDE V, IC50=0.6µM).

Product Specification

Alternative Name:1-(3-Chlorophenylamino)-4-phenylphthalazine
 
Formula:C20H14ClN3
 
MW:331.8
 
CAS:78351-75-4
 
Purity:≥98% (HPLC)
 
Identity:Determined by 1H-NMR and MS.
 
Appearance:Yellow solid.
 
Solubility:Soluble in DMSO (10mg/ml).
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at room temperature. Stock solutions are stable for up to 3 months at -20°C.
 
bml-pd155
Please mouse over
bml-pd155

Product Literature References

Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation: M. Shelly, et al.; Science 327, 547 (2010), Abstract;
cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo: H.L. Xu, et al.; Am. J. Physiol. Heart Circ. Physiol. 287, H2501 (2004), Abstract;
Inhibitory effects of natriuretic peptides on vasopressin neurons mediated through cGMP and cGMP-dependent protein kinase in vitro: N. Akamatsu, et al.; J. Neuroendocrinol. 5, 517 (1993), Abstract;
Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway: I.D. Durate, et al.; Eur. J. Pharmacol. 186, 289 (1990), Abstract;
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation: M. Hagiwara, et al.; J. Pharmacol. Exp. Ther. 228, 467 (1984), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
PDE
By biological activity:
PDE Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,